Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Imbruvica® (ibrutinib) – Expanded indication
August 27, 2018 - AbbVie announced the FDA approval of Imbruvica (ibrutinib) plus Rituxan® (rituximab), for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
